AgomAb Therapeutics NV - ADRs representing one common share

Moat components assessed for a pre‑revenue biotech: Intangible assets and IP (weight 50%, score 55): portfolio includes composition‑of‑matter and method‑of‑use protections for ontunisertib families and a U.S. composition‑of‑matter patent for AGMB‑447 through at least 2041; ontunisertib has FDA Fast Track status and Phase 2b design aligned with FDA.

These are real but early‑stage moats that depend on clinical success. Switching costs (weight 15%, score 10): low for prescribers and payers; adoption will hinge on clear clinical benefit and safety. Network effects (weight 0%, score 0): none.

Cost advantages (weight 15%, score 15): organ‑restricted delivery could lower systemic toxicities versus systemic TGF‑β/ALK5 inhibition, potentially easing long‑term safety management, but not yet proven as a durable cost edge.

Efficient scale (weight 20%, score 25): if first to market in FSCD, limited competitive capacity could create local efficient scale; however, this is contingent on clinical success and regulatory precedent. Weighted outcome yields a modest moat given binary risk and absence of commercial entrenchment.

Potential pricing power is meaningful if the programs succeed. FSCD currently lacks approved pharmacologic therapies; a safe, effective oral that reduces strictures and procedures could justify premium specialty pricing. IPF is an orphan disease with historically high pricing tolerance if safety and efficacy are strong.

Organ‑restricted mechanisms may aid risk‑benefit positioning. That said, all pricing power here is latent and contingent on pivotal data and payer acceptance of novel endpoints in FSCD, so we cap the score at moderate.

Revenue, earnings and FCF predictability are very low. Both lead assets are pre‑pivotal and outcomes are binary. The NOV‑ERA Phase 2b study introduces a novel primary endpoint (endoscopic passability) even though FDA alignment reduces regulatory risk.

AGMB‑447 enters a highly competitive and failure‑prone IPF field despite encouraging Phase 1 proof‑of‑mechanism. While the company has communicated timelines for Phase 2b/2 initiations in 2H26 and expects OLE and Phase 1b readouts in 2H26, the fundamental uncertainty remains high until robust, reproducible mid‑ to late‑stage efficacy data exist.

Cash, cash equivalents and short‑term investments totaled €252.0 million at June 30, 2026, supported by the February 2026 IPO that raised approximately $208 million gross and about $188 million net.

Management expects runway into 1H29. 2025 operating cash outflow was about €51.7 million; 1H26 R&D was €23.0 million and G&A €12.2 million, consistent with a controlled burn. Balance sheet shows minimal financial debt, with liabilities primarily lease and contingent consideration related to prior acquisition.

The strong cash position relative to burn supports a multi‑year plan through key data inflections.

Positive marks for focusing capital on organ‑restricted TGF‑β programs with promising early data, timing the IPO to extend runway into 1H29, and pursuing regulatory alignment ahead of a large Phase 2b. The company is exploring strategic options for AGMB‑101 rather than reflexively advancing all programs, which signals discipline.

Risks include the inherent dilution path of clinical biotechs if timelines extend or trials expand, and concentration in one biology (ALK5) across two indications.

CEO Tim Knotnerus has led Agomab since 2019 with prior BD experience; CMO Philippe Wiesel brings fibrosis development expertise; CFO Pierre Kemula previously served as CFO at CureVac, adding public‑company and financing depth. The board is being augmented in 2026 with experienced industry leaders.

Overall execution to date on financing, regulatory alignment, and trial progress is solid, though the team still must demonstrate pivotal‑stage execution and commercial build capabilities.